l   Qisda’s business groups all showed growth in Q2

l   The Medical and BSG businesses demonstrated steady growth and stability

Qisda’s (TWSE: 2352) operations across all business segments improved in the second quarter, with the Medical and BSG businesses both hitting new quarterly records. The Medical business exceeded NT$7 billion in revenue for the third consecutive quarter, while the BSG business reached NT$9.5 billion for the first time. Looking ahead to the third quarter, despite uncertainties related to tariffs and exchange rates, both the Medical and BSG businesses are expected to maintain steady growth.

Qisda held an online investor conference on August 14 to share its Q2 performance and Q3 outlook.

Qisda's Chairman, Peter Chen, stated that Qisda continues to make progress toward its 2027 goal of generating more than half of its profits from high value-added businesses. Both the Medical and BSG businesses have shown stable growth, contributing 14% and 17% of total revenue, respectively, in the first half of the year. These businesses are expected to remain key growth engines for this year.

Qisda's President, Joe Huang, noted that in response to tariff and exchange rate uncertainties, Qisda will enhance cost control, build a resilient supply chain, and invest in long-term growth momentum. He expressed optimism for year-over-year growth in the IT and NCG businesses in Q3. The Medical business will continue expanding into biomedical fields and pharmaceutical distribution channels, while the BSG business will focus on three core areas: computing power, software and services, and intelligent automation.

In terms of performance in each business group in Q2, the IT business achieved a 3% QoQ increase in revenue, while gross margin and operating income remained stable compared to the previous quarter. The Medical business posted a 7% QoQ revenue growth, with improvements in both operating margin and operating income. The BSG business saw an 18% QoQ increase in revenue, accompanied by higher operating margin and operating income. The NCG business experienced a 26% QoQ rise in revenue, though its operating income declined from the previous quarter.

Qisda 2025 Q2 Financial Highlights

Revenue: NT$53.464 billion, up 7% YoY and QoQ.

Gross Profit: NT$8.627 billion, up 4% YoY, slightly higher than Q1

Gross Margin: 16.1%, down 0.6 percentage points YoY and down 1.2 percentage points QoQ

Operating Income: NT$762 million, down 36% YoY and down 24% QoQ

Operating Income Margin: 1.4%, down 1 percentage point YoY and down 0.6 percentage points QoQ

Net Income: NT$370 million, down 54% YoY and down 38% QoQ

Net income Attributable to Qisda: NT$356 million, down 46% YoY and down 26% QoQ

Earnings Per Share (EPS): 0.18

Qisda 1H 2025 Financial Highlights

Revenue: NT$103.2 billion, up 7% YoY

Gross Profit: NT$17.249 billion, up 9% YoY

Gross Margin: 16.7%, up 0.3 percentage points YoY

Operating Income: NT$1.761 billion, down 17% YoY

Operating Income Margin: 1.7%, down 0.5 percentage points YoY

Net Income: NT$964 million, down 20% YoY

Net income Attributable to Qisda: NT$839 million, down 9% YoY

Earnings Per Share (EPS): 0.44